Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.11.13.623476Source: DataRank Database

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: greenTopics (30)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Keval Parikh ORCID,Jian Zhang ORCID,Alexander Brinkley,Grace Chen ORCID,Natnicha Jakramonpreeya

Live enrichment

PubMed:39605384 OpenAlex:https://openalex.org/W4404328215

National Institutes of Health

Grant: 5U19AI149504-03

(Attack)2: Genetic engineering of cellular and humoral immunity to cure HIV

National Institutes of Health

Grant: 5R01AI172727-03

Induction of autophagy to enhance CAR-T cells in HIV cure approaches

National Institutes of Health

Grant: 5R01DA052841-04

Define the effects and mechanism of THC and CBD on IFN-I mediated inflammation and immune dysfunction during HIV infection

National Institutes of Health

Grant: 3P30AI152501-03S1

UCLA-CDU CFAR

NIAID NIH HHS

Grant: P30 AI152501

NIAID NIH HHS

Grant: R01 AI172727

NIDA NIH HHS

Grant: R01 DA052841

NIAID NIH HHS

Grant: U19 AI149504

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2024/11/13/2024.11.13.623476.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2024.11.13.623476

repositoryhttps://doi.org/10.1101/2024.11.13.623476

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39605384

Fields of Study

Virus-based gene therapy researchCAR-T cell therapy researchCRISPR and Genetic Engineering0301 basic medicine03 medical and health sciences

Keywords

Human immunodeficiency virus (HIV)VirologyGenetic enhancementGeneMedicineBiologyImmunologyGeneticsCD4-based anti-HIV-1 chimeric antigen receptorQH573-671truncated human EGFR, huEGFRtQH426-470ArticleC46 membrane-anchored HIV-1 fusion inhibitorhematopoietic stem/progenitor cell (HSPC)-based gene therapyHIV-1Original ArticleCCR5 short hairpin RNACytologyC46 membrane anchored HIV-1 fusion inhibitorCCR5 short-hairpin RNACetuximab-mediated in vivo negative selectionHematopoietic stem/progenitor cell (HSPC) based gene therapyhumanized mousetruncated human EGFR (huEGFRt)

Sustainable Development Goals

SDG 0: Good health and well-being